How many drugs treat Inactive tuberculosis?

Drug Landscape tracks 3 marketed treatments for Inactive tuberculosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/inactive-tuberculosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Inactive tuberculosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inactive tuberculosis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Inactive tuberculosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rifadin	Rifampicin	Sanofi Aventis Us	Rifamycin Antibacterial [EPC]	Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein	1971-01-01
Isoniazid	ISONIAZID	Epic Pharma Llc	Antimycobacterial [EPC]	Myeloperoxidase	1952-01-01
isoniazide	isoniazide	Bridge BioResearch Ltd.		Myeloperoxidase, Cytochrome P450 3A4, Cytochrome P450 3A5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bridge BioResearch Ltd. · 1 drug in Inactive tuberculosis
Epic Pharma Llc · 1 drug in Inactive tuberculosis
Sanofi Aventis Us · 1 drug in Inactive tuberculosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Inactive tuberculosis:

Cite this brief

Drug Landscape (2026). Inactive tuberculosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/inactive-tuberculosis. Accessed 2026-06-10.

Inactive tuberculosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing